Connect with us

Technology

IDEAYA Biosciences Announces the Promotion of Dr. Michael White to President, Research and Development

Published

3 hours ago

on

SOUTH SAN FRANCISCO, Calif., Sept. 28, 2026 /PRNewswire/ — IDEAYA Biosciences, Inc. (NASDAQ: IDYA), a precision medicine oncology company committed to the discovery and development of targeted therapeutics, today announced the promotion of Dr. Michael White, from Chief Scientific Officer to President, Research and Development, effective September 28, 2026. 

“I am excited to announce this well-deserved promotion for Mike, as President of Research and Development. During Mike’s 5-year tenure as Chief Scientific Officer, he has demonstrated exceptional leadership and has been a key driver in advancing IDEAYA’s mission to deliver patient impact in areas of high unmet medical need through R&D innovation. Under Mike’s leadership, I am excited to see the continued advancement of our industry leading precision medicine oncology pipeline targeting multiple solid tumor indications, including uveal melanoma, pancreatic cancer, small cell lung cancer, non-small cell lung cancer, colorectal cancer, breast cancer, among others,” said Yujiro S. Hata, President and Chief Executive Officer of IDEAYA Biosciences, Inc.

“I am honored to take on this expanded role at such a pivotal time for IDEAYA and grateful for the extraordinary commitment of our research and development teams. We have made tremendous progress in translating our precision medicine capabilities into a deep and differentiated oncology portfolio, with late-stage programs that have the potential to establish new standards of care and early-stage programs that may open entirely new therapeutic opportunities. I am particularly excited by our ability to advance innovative small molecules and antibody-drug conjugates for molecularly defined cancers where patients continue to face significant unmet need. I look forward to building on this momentum and accelerating the delivery of transformative therapies that can meaningfully improve and extend the lives of patients with cancer,” said Dr. Michael White, President, Research and Development, IDEAYA Biosciences, Inc. 

Dr. White has served as Chief Scientific Officer at IDEAYA Biosciences since 2021. Prior to IDEAYA, Dr. White served as Chief Scientific Officer and Head of Tumor Biology at Pfizer, Inc., where he led cross-disciplinary groups in research and development to build an oncology small-molecule clinical pipeline focused on first-in-class therapies, culminating in numerous INDs and late-stage development programs. Prior to joining Pfizer, Dr. White had a prolific over twenty-year academic career at UT Southwestern where he was a Professor of Cell Biology and founding Director of the Cancer Intervention and Prevention Discovery Program. In 2015, Dr. White received the inaugural Outstanding Investigator’s Award from the National Cancer Institute (NCI), the U.S. Government’s principal agency for cancer research, and has authored over 150 publications with over 30,000 citations. Dr. White received his Ph.D. in Biology from the University of North Carolina at Chapel Hill and completed postdoctoral research at Cold Spring Harbor Laboratories in New York.

About IDEAYA Biosciences

IDEAYA is a precision medicine oncology company committed to the discovery, development, and commercialization of transformative therapies for cancer. Our approach integrates expertise in small-molecule drug discovery, structural biology and bioinformatics with robust internal capabilities in identifying and validating translational biomarkers to develop tailored, potentially first-in-class targeted therapies aligned to the genetic drivers of disease. We have built a deep pipeline of product candidates focused on synthetic lethality and antibody-drug conjugates, or ADCs, for molecularly defined solid tumor indications. Our mission is to bring forth the next wave of precision oncology therapies that are more selective, more effective, and deeply personalized with the goal of altering the course of disease and improving clinical outcomes for patients with cancer.

Forward-Looking Statements

This press release contains forward-looking statements, including, but not limited to, statements regarding IDEAYA’s research and development strategy and objectives; the expected contributions of Dr. Michael White in his expanded role as President, Research and Development; the continued advancement of IDEAYA’s precision medicine oncology pipeline; the potential of IDEAYA’s late-stage programs to establish new standards of care and its early-stage programs to create new therapeutic opportunities; IDEAYA’s ability to develop and advance innovative small-molecule therapies and antibody-drug conjugates for molecularly defined cancers; and the potential for IDEAYA’s product candidates to improve and extend the lives of patients with cancer. 

These forward-looking statements are based on management’s current expectations and assumptions and are subject to a number of risks, uncertainties, and other factors that could cause actual results to differ materially from those described in the forward-looking statements. Such risks and uncertainties include, but are not limited to: risks related to the timing, progress, and results of clinical trials and preclinical studies; the ability of IDEAYA to obtain and maintain regulatory approvals; uncertainties regarding the regulatory review process, including participation in the RTOR program; the potential for clinical data to differ from preliminary or interim results; the ability to successfully develop, manufacture, and commercialize product candidates; competition from other biotechnology and pharmaceutical companies; the impact of global economic conditions; IDEAYA’s ability to successfully establish, protect and defend its intellectual property: and other risks described in IDEAYA’s filings with the U.S. Securities and Exchange Commission (SEC), including its most recent Quarterly Report on Form 10-Q and Annual Report on Form 10-K.

Forward-looking statements speak only as of the date of this press release, and IDEAYA undertakes no obligation to update or revise any forward-looking statements, whether as a result of new information, future events, or otherwise, except as required by law.

Investor and Media Contact
IDEAYA Biosciences
Joshua Bleharski
Chief Financial Officer
investor@ideayabio.com

View original content to download multimedia:https://www.prnewswire.com/news-releases/ideaya-biosciences-announces-the-promotion-of-dr-michael-white-to-president-research-and-development-302890666.html

SOURCE IDEAYA Biosciences, Inc.

Related Topics:
Continue Reading

Technology

Integrated Water Services Rebrands as Veyra to Lead Next Era of Advanced Water, Wastewater, and Filtration Solutions

Published

2 seconds ago

on

September 28, 2026

By

AUSTIN, Texas, Sept. 28, 2026 /PRNewswire/ — Integrated Water Services (IWS), an industry leader in specialized industrial and municipal water, wastewater and filtration solutions, announced today that it has officially changed its corporate name to Veyra (pronounced VAY-ruh). The comprehensive rebrand includes a new corporate identity, modern visual hierarchy, and an upgraded digital platform, launching live at WEFTEC 2026, in New Orleans.

The name Veyra is inspired by the Latin vera and pura—meaning true, pure, and authentic—with the dynamic root vey, representing conveyance and continuous flow. Anchored by the company’s new tagline “Purity by Design,” the elevated brand signals the company’s strategic transformation from legacy field construction into a cohesive, technology-first solutions platform.

Central to the new visual identity is Veyra’s logo icon, which features a fluid, three-dimensional Möbius strip. The Möbius form was chosen to communicate circularity—serving as a visual metaphor for water being continuously recovered, treated, reused, and returned to the ecosystem. The seamless, infinite loop encapsulates Veyra’s focus on sustainable water reclamation and advanced process filtration.

“Veyra represents the purity of our engineering, the velocity of our growth, and our focus on solving our customers’ toughest filtration, water and wastewater challenges,” said Cody Phipps, Chief Executive Officer. “Over the past three years, we’ve rapidly expanded our proprietary technologies and integrated key acquisitions to deliver capabilities no single company in this space has had before. Veyra is the name our clients’ next generation of solutions deserves.”

What’s changing — and what isn’t:

One Company, Specialized Brands: Veyra creates a unified corporate platform for M|MBR Systems, Complete Filtration Resources, Tetrasolv, KLa Systems, and Advanced Equipment & Services Inc., while preserving the specialized expertise, customer relationships and market identity of each business.One Integrated Portfolio: Veyra brings advanced MBR systems, modular wastewater infrastructure, specialized filtration, aeration systems, and aftermarket services together under one strategic architecture.A More Connected Customer Experience: Veyra’s new digital platform provides centralized access to technical documentation, engineering resources, solution information and lifecycle support, making it easier for customers and partners to engage with capabilities across the portfolio.

“Our commitment to clients and partners remains absolute,” said John Rigas, Chairman and CEO of Sciens Water. “As Veyra, the company is sharpening its commercial edge and giving its teams a brand that matches the sophistication of what they deliver.”

Veyra will debut its new identity at Booth #335 at WEFTEC this week, and online at www.goveyra.com.

About Veyra

www.goveyra.com

Veyra delivers modular, scalable process water and wastewater solutions for municipal, commercial, and industrial customers — combining advanced treatment technology, precision filtration, intelligent controls, and lifecycle support. Veyra is headquartered in Austin, Texas.

About Sciens Water Opportunities Management, LLC

www.scienswater.com

Sciens Water, the fund manager of the majority shareholders of IWS, is an affiliate of Sciens Capital Management, LLC, an alternative asset management firm founded in 1994. With headquarters in New York and an office in London, Sciens launched the Sciens Water Opportunities Fund in 2018 to invest in the U.S. water sector. Sciens’ approach is to identify the biggest challenges facing the U.S. water and wastewater industry today and solve them through the formation and development of platform companies that seek to meet these challenges on a national scale with a high level of purpose and impact on health, the environment, and local economies. Sciens has invested in platform companies in several water sub-sectors, including utilities, treatment, storage, financing, and digital infrastructure.

Media Contact
Jamie English
Veyra
jenglish@goveyra.com

View original content to download multimedia:https://www.prnewswire.com/news-releases/integrated-water-services-rebrands-as-veyra-to-lead-next-era-of-advanced-water-wastewater-and-filtration-solutions-302890798.html

SOURCE Integrated Water Services, Inc.

Continue Reading

Technology

Cosmos Provides Connectivity to Help Banks Participate in Swift’s Ledger for 24/7 Cross-Border Payments

Published

3 seconds ago

on

September 28, 2026

By

The Cosmos Tokenization Suite gives financial institutions access to capabilities like 24/7 cross-border payments by integrating with key networks like Swift’s blockchain-based ledger.

NEW YORK, Sept. 28, 2026 /PRNewswire/ — Cosmos helps banks and financial institutions connect their core ledger to EVM and Hyperledger Besu environments, such as the one powering Swift’s blockchain-based shared ledger, to support use cases like 24/7 cross-border payments.

The Cosmos Tokenization Suite gives banks the infrastructure to stand up their own tokenized deposit ledgers, synchronize them with existing cores, like Fiserv, FIS, Jack Henry, Temenos, and Hogan, and connect them with networks like Swift’s ledger, Canton, Partior, Ethereum, Solana, and more. Swift’s ledger provides secure messaging and orchestration, while the Cosmos platform gives financial institutions a seamless path to move customer funds across counterparties.

Building on that foundation, Cosmos accelerates three key areas for banks participating in the Swift pilot. The first is integration between core banking systems and digital ledgers, including EVM and Hyperledger-based environments, like Swift’s ledger. It also accelerates interoperability across networks and counterparties and, in the future, will support engagement with correspondent banks to enable broader participation.

“For our clients, this is about helping them connect their core ledger to external networks via their existing infrastructure and relationships. Banks need to offer customers 24/7 payments and real-time treasury experiences. Cosmos offers the connectivity to make that possible across counterparties, starting now,” said Maghnus Mareneck, Co-CEO, Cosmos.

Beyond payments, the Cosmos Tokenization Suite unlocks a broader set of use cases, such as real-time treasury management, instant cash sweeps, and programmable money flows.

Swift’s ledger provides a secure orchestration layer that enables 24/7 cross-border payments using tokenized deposits, while keeping those deposits on banks’ balance sheets and preserving the benefits of commercial bank money. With Cosmos, the tokenized deposits remain on the issuing bank’s ledger; Swift’s ledger securely orchestrates the movement of funds between participating institutions, including overnight and on weekends, before completing final settlement through existing systems.

Today, value equivalent to global GDP moves across the Swift network every two to three days, and 75% of transactions on Swift already reach the end bank within ten minutes. The addition of a blockchain-based ledger to Swift’s infrastructure does not alter its role as a global financial messaging network. Final settlement continues through agreed mechanisms, including real-time gross settlement systems. This allows banks to extend payment availability beyond traditional operating hours while retaining their existing settlement arrangements.

The MVP of Swift’s ledger was developed in collaboration with more than 40 financial institutions globally. Seventeen first-mover financial institutions are now putting it into practice, piloting tokenized deposit transactions across a range of use cases. The initiative builds on the Swift co-operative’s global reach of more than 12,500 financial institutions and corporates across over 200 markets.

About Cosmos

Cosmos Labs is the company leading development and growth for Cosmos, the world’s leading neutral, open-source digital ledger ecosystem powering 150+ chains across finance, payments, and global business. Cosmos offers blockchain infrastructure and solutions for financial institutions to drive digital transformation. To learn more, follow @cosmos on X or visit cosmos.network.

CONTACT: cosmos@5wpr.com

View original content to download multimedia:https://www.prnewswire.com/news-releases/cosmos-provides-connectivity-to-help-banks-participate-in-swifts-ledger-for-247-cross-border-payments-302891523.html

SOURCE Cosmos Labs

Continue Reading

Technology

Microfluidics Market to Reach US$ 43 Bn by 2031, Growing at 9.8% CAGR as Point-of-Care and Organ-on-Chip Adoption Expands: New Report by Wissen Research

Published

5 seconds ago

on

September 28, 2026

By

SHERIDAN, Wyo., Sept. 28, 2026 /PRNewswire/ — The global microfluidics market is projected to grow from USD 26.9 billion in 2026 to USD 43 billion by 2031, registering a CAGR of 9.8% during the forecast period (2026–2031), according to a new study by Wissen Research.

Growth is being driven by rising demand for point-of-care testing and decentralized diagnostics, expanding use of precision medicine, and sustained pharmaceutical and biotech investment in organ-on-a-chip and droplet-based single-cell systems. Microfluidic platforms handle liquids at the microliter and nanoliter scale inside engineered channels, which cuts sample and reagent volumes, speeds up analysis, and moves testing closer to the patient, the research bench, and the field.

Get a Free Sample of This Report to Explore Key Findings and Data: https://www.wissenresearch.com/request-a-sample/?report=microfluidics-market

Where the Technology Is Heading: Integrated Chips, Smarter Readers

The most visible shift in microfluidics is the move from single-function chips, which run one test, to fully integrated sample-to-answer cartridges that combine sample preparation, amplification, and detection on a single chip. Manufacturers are extending chip integration into multifunctionality and coupling the hardware with AI-driven analysis software, allowing platforms once confined to specialized labs to operate in clinical and field environments.

Machine-learning algorithms are increasingly built into handheld and benchtop readers to analyze fluorescence, morphology, and other optical signals, supporting automated interpretation, quantitative output, and the standardized data capture and traceability that regulated diagnostic workflows require.

In pharmaceutical research, organ-on-a-chip models are gaining ground as a complement to conventional cell and animal-based models in early toxicity and efficacy testing. Multi-organ designs that link several tissue types on one platform are beginning to move from academic proof-of-concept into contract-research service offerings.

What’s Fueling Growth in the Microfluidics Market

Point-of-Care and Decentralized Diagnostics: Demand is rising for platforms that shorten the path between sample collection and clinical decision-making.Precision Medicine Expansion: Personalized medicine increasingly relies on high-throughput, low-volume molecular profiling that microfluidic platforms support cost-effectively.Pharma and Biotech R&D Investment: Sustained spending on organ-on-a-chip and droplet-based single-cell systems is broadening use in early-stage drug discovery.AI-Integrated Lab-on-Chip Analytics: Multiplexed on-chip assays and automated interpretation are widening the range of clinical and research use cases.Infrastructure Build-Out in Developing Economies: Rapid growth in diagnostic and life-science research infrastructure is opening new demand.Manufacturing Partnerships: Supply agreements between chip makers and diagnostic companies are easing production bottlenecks and shortening time to market.

Challenges Facing the Microfluidics Market

Cost and validation remain the main brakes on adoption. Microfluidic instrumentation carries high initial costs compared with conventional laboratory equipment, and validating new platforms adds further expense, which is particularly difficult for smaller research laboratories and cost-conscious institutions to absorb. Established laboratory procedures also resist change, even where a new format offers clear speed or volume advantages.

Regulation is another source of uncertainty. Frameworks continue to lag technology, especially for organ-chip platforms and multiplex diagnostics, and the treatment of formats designed to complement or reduce reliance on certain animal-based studies is still evolving. That makes long-range product planning harder for manufacturers. Some applications also still require trained personnel, specialized readers, and quality control procedures before clinical deployment.

Recent Strategic Developments in the Microfluidics Market

In August 2026, HyperMelt, a U.S. diagnostics startup, was reported to be developing a microfluidics-based platform that combines sample digitization with thermal analysis to improve molecular characterization of cancer-related biomarkers, with potential applications in early cancer detection and liquid biopsy workflows.

In April 2025, CEA-Leti and Infiplast of France launched a dedicated microfluidics initiative to accelerate the industrialization and manufacturing of healthcare-oriented microfluidic devices, helping move laboratory-developed technologies into commercial products.

In November 2024, Parallel Fluidics secured USD 7 million in seed funding to accelerate its microfluidic manufacturing platform for life science applications including IVF, biotechnology research, and advanced laboratory workflows.

Taken together, these moves point to an industry focused on scaling manufacturing, moving lab-built devices to market, and extending microfluidics into oncology and reproductive health.

Key Insights from Microfluidics Market Analysis

In vitro diagnostics dominates total consumption by application, spanning infectious disease panels, cardiac markers, and molecular point-of-care tests, while pharmaceutical and life sciences research is the rapidly growing segment, driven by proteomics, genomics, and organ-on-a-chip work.Consumables, including disposable chips, cartridges, and assay-specific products, represent a significant recurring-revenue segment, as they are replaced with each increase in testing volume, unlike capital-intensive instruments and readers.North America led the market in 2025, supported by established diagnostics and life science companies, a mature biotechnology ecosystem, deep R&D investment, and available venture capital.Asia-Pacific is the fastest-growing region, driven by diagnostics and research infrastructure investment, chronic and infectious disease prevalence, and government support for local microfluidic device manufacturing in China, India, and Japan.Competition runs on two models: diversified life-science companies offering integrated chip, instrument, consumable, and software workflows, and specialists focused on fabrication, organ-on-chip platforms, droplet generation, or flow control.

Key Players in the Microfluidics Market

Leading companies in the microfluidics market are focused on product innovation, lab-on-chip platform development, integration of microfluidics with molecular diagnostics and single-cell analysis, strategic collaborations, and manufacturing expansion.

Company

Key Focus Area

Thermo Fisher Scientific Inc. (US)

Life science instruments and consumables

Illumina, Inc. (US)

Sequencing and library preparation platforms

Bio-Rad Laboratories, Inc. (US)

Life science research and clinical diagnostics

Danaher Corporation (US)

Diagnostics and life sciences instrumentation

Agilent Technologies, Inc. (US)

Analytical instruments and life sciences tools

F. Hoffmann-La Roche Ltd (Switzerland)

Diagnostics platforms

bioMérieux (France)

Infectious disease diagnostics

Becton, Dickinson and Company (US)

Diagnostic instruments and consumables

Abbott Laboratories (US)

Diagnostics and point-of-care testing

10x Genomics (US)

Single-cell analysis platforms

Emulate (US)

Organ-on-chip technology

Dolomite Microfluidics (UK)

Droplet and microfluidic systems

Regional Analysis and Growth Opportunities

North America leads the microfluidics market, backed by a strong base of established diagnostics and life science companies, a mature biotechnology ecosystem, significant R&D investment, and a dense network of device manufacturers, component suppliers, and research institutions across major biotech clusters. The region’s experience with regulatory pathways for diagnostic technologies further supports commercialization and adoption.

Asia-Pacific is the fastest-growing region, with rising investment in diagnostics and research infrastructure, a growing burden of chronic and infectious disease, and government support for local manufacturing of microfluidic devices. Growing R&D spending and cross-border manufacturing collaborations in China, India, and Japan are positioning the region as an important contributor to global demand.

Europe, Latin America, and the Middle East & Africa complete the report’s regional coverage, with growth shaped by expanding diagnostic capacity and rising research investment.

Get a Custom Briefing on This Market for Your Business

Wissen Research’s technology analysts are available to walk through findings specific to your market, region, or competitive set.

Need Insights Specific to Your Business? Request a Customized Version of This Report: https://www.wissenresearch.com/request-customization/?report=microfluidics-market

Market Segmentation Snapshot

The global microfluidics market is segmented across product type, material, technology, application, end user, and region:

By Product Type: Microfluidic-Based Devices (Lab-on-a-Chip, Organ-on-a-Chip, Microfluidic PCR Platforms, Capillary Electrophoresis Systems, NGS Library Preparation Platforms, Droplet & Particle Production Systems)Microfluidic Components (Chips, Flow & Pressure Sensors, Flow & Pressure Controllers, Valves, Micropumps, Microneedles)By Material: SiliconGlassPolymer Materials (PDMS, PMMA, COC, Others)Paper & Other Porous SubstratesOther MaterialsBy Technology: Continuous-Flow MicrofluidicsDigital/Droplet MicrofluidicsOrgan-on-Chip & Tissue-Chip TechnologyElectrophoretic MicrofluidicsOptofluidicsAcoustofluidics & ElectrowettingCentrifugal MicrofluidicsPaper-Based MicrofluidicsBy Application: In Vitro Diagnostics (Clinical Diagnostics, Point-of-Care Testing, Veterinary Diagnostics)Pharmaceutical & Life Science ResearchTherapeutics (Drug Delivery, Wearable Therapeutic & Monitoring Devices)Environmental & Food Safety TestingOther ApplicationsBy End User: Hospitals & Diagnostic Centers/LaboratoriesPharmaceutical & Biotechnology CompaniesAcademic & Research InstitutesCROs/CMOsForensic & Environmental Testing LaboratoriesOthersBy Region: North AmericaEuropeAsia-PacificLatin AmericaMiddle East & Africa

Frequently Asked Questions

Q: What is the size of the microfluidics market? 

A: The global microfluidics market is estimated at USD 26.9 billion in 2026 and is projected to reach USD 43 billion by 2031.

Q: What is the growth rate of the microfluidics market? 

A: The microfluidics market is projected to grow at a CAGR of 9.8% between 2026 and 2031.

Q: Which application dominates the microfluidics market? 

A: In vitro diagnostics dominates total consumption, covering infectious disease panels, cardiac markers, and molecular point-of-care tests, while pharmaceutical and life sciences research is the fastest-growing application segment.

Q: Which region leads the microfluidics market? 

A: North America led the microfluidics market in 2025, while Asia-Pacific is the fastest-growing region through 2031.

Q: What is organ-on-a-chip technology? 

A: Organ-on-a-chip devices use microfluidic channels to mimic the mechanical and biochemical conditions of specific human tissues, and pharmaceutical companies use them in early toxicity and efficacy testing to complement conventional cell culture and animal-based models.

Q: Who are the top players in the microfluidics market? 

A: Leading players in the microfluidics market include Thermo Fisher Scientific Inc., Illumina, Inc., Bio-Rad Laboratories, Inc., Danaher Corporation, and Agilent Technologies, Inc.

As integrated sample-to-answer cartridges, AI-enabled analytics, and organ-on-a-chip models continue to mature, microfluidics is becoming a core enabling technology across diagnostics, drug discovery, and life science research. For manufacturers, the path forward lies in scalable production, regulatory readiness, and platforms that lower the cost of moving from laboratory to point of care.

Get the Complete Microfluidics Market Report — Forecasts, Insights & Growth Opportunities: https://www.wissenresearch.com/market-research-reports-pricings/microfluidics-market

Expert Profile | Mayur Jain, Wissen Research 

Mayur Jain is a Research Expert at Wissen Research with multidomain expertise with more than 12+ years of experience in market research industry. 

Email: mayur@wissenresearch.com
LinkedIn:  https://www.linkedin.com/in/mayur-jain-0190542a/ 

About Wissen Research

Wissen Research is a global market intelligence and consulting firm specializing in healthcare, life sciences, technology, and emerging industries. The company provides data-driven insights, strategic market analysis, and industry forecasts to help organizations make informed business decisions and identify new growth opportunities across global markets

Company Contact:

Wissen Research LLC,
Gould St, Ste R,
Sheridan, WY 82801,
Phone: (+1) 510 240 9853
Email: info@wissenresearch.com
Website: https://www.wissenresearch.com/
Blog: https://www.wissenresearch.com/insights/
LinkedIn: https://www.linkedin.com/company/wissen-research 

 

View original content to download multimedia:https://www.prnewswire.co.uk/news-releases/microfluidics-market-to-reach-us-43-bn-by-2031–growing-at-9-8-cagr-as-point-of-care-and-organ-on-chip-adoption-expands-new-report-by-wissen-research-302891528.html

Continue Reading

Trending